DDrare: Database of Drug Development for Rare Diseases

Sirolimus, 2% (DrugBank: Sirolimus)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
36	表皮水疱症	1
192	コケイン症候群	1

36. 表皮水疱症　［臨床試験数：147，薬物数：170（DrugBank：40），標的遺伝子数：32，標的パスウェイ数：113］

Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 147 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02960997 (ClinicalTrials.gov)	May 2016	15/6/2016	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus, 2%;Drug: Vehicle	Stanford University	NULL	Active, not recruiting	4 Years	N/A	All	8	Phase 2	United States

192. コケイン症候群　［臨床試験数：4，薬物数：7（DrugBank：3），標的遺伝子数：1，標的パスウェイ数：50］

Searched query = "Cockayne syndrome", "CS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 4 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02960997 (ClinicalTrials.gov)	May 2016	15/6/2016	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)	Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome	Drug: Sirolimus, 2%;Drug: Vehicle	Stanford University	NULL	Active, not recruiting	4 Years	N/A	All	8	Phase 2	United States